Search Results - "Gaussem, P"

Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin by Gouin‐Thibault, I., Delavenne, X., Blanchard, A., Siguret, V., Salem, J. E., Narjoz, C., Gaussem, P., Beaune, P., Funck‐Brentano, C., Azizi, M., Mismetti, P., Loriot, M. A.

“…Essentials Rivaroxaban and dabigatran are substrates of the P‐glycoprotein (P‐gp) encoded by the ABCB1 gene. We tested the effect of ABCB1 polymorphisms and of…”
Get full text

Prospective observational study of the effect of dual antiplatelet therapy with tranexamic acid treatment on platelet function and bleeding after cardiac surgery by Amour, J., Garnier, M., Szymezak, J., Le Manach, Y., Helley, D., Bertil, S., Ouattara, A., Riou, B., Gaussem, P.

“…The bleeding impact of dual antiplatelet therapy (DAPT), aspirin and clopidogrel, maintained until coronary artery bypass graft surgery (CABG), is still a…”
Get full text

Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects by FONTANA, P., HULOT, J.‐S., DE MOERLOOSE, P., GAUSSEM, P.

Get full text

Distinct patterns of circulating endothelial cells in pulmonary hypertension by SMADJA, D. M, MAUGE, L, SANCHEZ, O, SILVESTRE, J.-S, GUERIN, C, GODIER, A, HENNO, P, GAUSSEM, P, ISRAËL-BIET, D

“…The respective abundance of circulating endothelial cells and endothelial progenitor cells may reflect the balance between vascular injury and repair. As…”
Get full text

Multimodal assessment of non‐specific hemostatic agents for apixaban reversal by Martin, A.‐C., Gouin‐Thibault, I., Siguret, V., Mordohay, A., Samama, C.‐M., Gaussem, P., Le Bonniec, B., Godier, A.

“…Summary Background Non‐specific hemostatic agents, namely activated prothrombin complex concentrate (aPCC), PCC and recombinant activated factor (F) VII…”
Get full text

Pulsed cavitational therapy using high-frequency ultrasound for the treatment of deep vein thrombosis in an in vitro model of human blood clot by Goudot, G, Mirault, T, Arnal, B, Boisson-Vidal, C, Le Bonniec, B, Gaussem, P, Galloula, A, Tanter, M, Messas, E, Pernot, M

“…Post-thrombotic syndrome, a frequent complication of deep venous thrombosis, can be reduced with early vein recanalization. Pulsed cavitational therapy (PCT)…”
Get more information

The profibrotic cytokine transforming growth factor‐β1 increases endothelial progenitor cell angiogenic properties by EVRARD, S. M., D′AUDIGIER, C., MAUGE, L., ISRAËL‐BIET, D., GUERIN, C. L., BIECHE, I., KOVACIC, J. C., FISCHER, A.‐M., GAUSSEM, P., SMADJA, D. M.

“…Background:  Transforming growth factor‐β1 (TGF‐β1) is a profibrotic cytokine that plays a major role in vascular biology, and is known to regulate the…”
Get full text

Angiogenic potential of BM MSCs derived from patients with critical leg ischemia by Smadja, D M, d'Audigier, C, Guerin, C L, Mauge, L, Dizier, B, Silvestre, J-S, Cortivo, L Dal, Gaussem, P, Emmerich, J

Get full text

Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase‐activated receptor‐1 (PAR1) antagonist by Dumas, M, Nadal‐Wollbold, F, Gaussem, P, Perez, M, Mirault, T, Létienne, R, Bourbon, T, Grelac, F, Le Grand, B, Bachelot‐Loza, C

“…BACKGROUND AND PURPOSE New antithrombotic agents with the potential to prevent atherothrombotic complications are being developed to target receptors on…”
Get full text

Elevated plasma fibrin D‐dimer as a risk factor for vascular dementia: the Three‐City cohort study by CARCAILLON, L., GAUSSEM, P., DUCIMETIÈRE, P., GIROUD, M., RITCHIE, K., DARTIGUES, J. F., SCARABIN, P. Y.

“…Background: Hemostatic biomarkers have been associated with coronary heart disease (CHD) and stroke. However, few studies have investigated these associations…”
Get full text

Platelet dysfunction associated with the novel Trp29Cys thromboxane A2 receptor variant by Mumford, A. D., Nisar, S., Darnige, L., Jones, M. L., Bachelot‐Loza, C., Gandrille, S., Zinzindohoue, F., Fischer, A.‐M., Mundell, S. J., Gaussem, P.

“…Summary Background Genetic variations that affect the structure of the thromboxane A2 receptor (TP receptor) provide insights into the function of this key…”
Get full text

Endothelial progenitor cells: characterization, in vitro expansion, and prospects for autologous cell therapy by Smadja, D M, Cornet, A, Emmerich, J, Aiach, M, Gaussem, P

“…Injection of hematopoietic stem cells or endothelial progenitor cells (EPCs) expanded ex vivo has been shown to augment neovascularization in adult patients,…”
Get full text

Vascular endothelial growth factor, as compared with placental growth factor, is increased in severe sepsis but not in organ failure by SMADJA, D. M., BORGEL, D., DIEHL, J.‐L., GAUSSEM, P.

Get full text

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies by GAUSSEM, P., RENY, J.‐L., THALAMAS, C., CHATELAIN, N., KROUMOVA, M., JUDE, B., BONEU, B., FIESSINGER, J.‐N.

“…Objectives and patients: We conducted a multicenter double‐blind pharmacokinetic/pharmacodynamic (PK/PD) study of the new oral thromboxane receptor antagonist…”
Get full text

Antiplatelet agents and transfusion by Gaussem, P, Martin, A-C, Belleville-Rolland, T, Helley, D, Bachelot-Loza, C, Godier, A

“…Antiplatelet agents are at risk for bleeding complications, the management of which differs depending on the clinical situation and on the antiplatelet agent…”
Get more information

Proton pump inhibitors and clopidogrel: a hazardous association? by Szymezak, J, Gaussem, P

“…Proton pump inhibitors (PPI) and antiplatelet agents, especially aspirin and clopidogrel, are among the most prescribed medications worldwide. Their…”
Get full text

Effect of an increased clopidogrel maintenance dose or lansoprazole co‐administration on the antiplatelet response to clopidogrel in CYP2C19‐genotyped healthy subjects by HULOT, J.‐S., WUERZNER, G., BACHELOT‐LOZA, C., AZIZI, M., BLANCHARD, A., PEYRARD, S., FUNCK‐BRENTANO, C., GAUSSEM, P.

Get full text

The angiopoietin pathway is modulated by PAR‐1 activation on human endothelial progenitor cells by SMADJA, D. M., LAURENDEAU, I., AVIGNON, C., VIDAUD, M., AIACH, M., GAUSSEM, P.

“…Objectives: The importance of protease‐activated receptor‐1 (PAR‐1) in blood vessel development has been shown in knock‐out mice. As endothelial progenitor…”
Get full text

Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome by Smadja, DM, Gaussem, P., Roncal, C., Fischer, A-M., Emmerich, J., Darnige, L.

“…Antiphospholipid syndrome (APS) is defined as a combination of antiphospholipid antibodies, arterial and/or venous thrombosis, and, in women, recurrent fetal…”
Get full text

Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days by Siguret, V, Pautas, E, Février, M, Wipff, C, Durand-Gasselin, B, Laurent, M, Andreux, J P, d'Urso, M, Gaussem, P

“…Since low molecular weight heparins (LMWH) are partly eliminated by renal excretion, their pharmacodynamic profile may be modified in very elderly patients…”
Get more information